Avanos Medical
NYSE: AVNS
$24.99 ▲ +0.01  (+0.04%)
At close: Jul 24, 2026 · 4:03 PM UTC
Financial Ratios
Market Cap1.16 Bn
P/E227.76
P/S1.62
Div. Yield0.00
ROIC (Qtr)-0.02
Total Debt (Qtr)98.20 Mn
Revenue Growth (1y) (Qtr)8.78
Add ratio to table…

About

Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. The company develops, manufactures and markets its recognized brands globally, addressing healthcare needs such as providing a vital lifeline for nutrition from hospital to home and reducing opioid use while helping patients move from surgery to recovery. It operates in two reportable segments,…

Read more ↓
Sector: Healthcare Industry: Medical Devices CIK: 0001606498

Investment Thesis

▲ Bull case
  • Avanos Medical's Specialty Nutrition Systems segment continues to show robust organic growth, delivering 22.7% year-over-year revenue increase in Q1 FY26 driven by strong performance in both enteral feeding (13.6%) and neonate solutions (48.1%), indicating sustained demand for its core nutrition products despite macroeconomic headwinds, which positions the company to capitalize on aging demographics and rising chronic disease prevalence globally.
  • The pending acquisition by American Industrial Partners at $25.00 per share represents a significant premium to current trading levels and validates the underlying value of Avanos' market-leading positions in specialty nutrition and pain management, providing near-term liquidity for shareholders while enabling long-term strategic investments under AIP's operational expertise that could unlock further growth in radiofrequency ablation and surgical recovery platforms.
  • CMS's expansion of the NOPAIN Act reimbursement for Avanos' Game Ready GRPro 2.1, ON-Q, and ambIT infusion systems creates a durable tailwind for its Pain Management & Recovery segment, as separate Medicare payment eligibility in hospital outpatient and ambulatory surgical center settings enhances adoption potential and reduces barriers to uptake of non-opioid alternatives, directly addressing a major healthcare priority and supporting pricing power in a competitive landscape.
  • Ongoing strategic initiatives such as the co-marketing agreement with Siemens Healthineers to integrate RFA technologies with advanced imaging are not heavily promoted in recent communications but represent a hidden catalyst that could improve clinical workflow, expand access to outpatient pain procedures, and strengthen Avanos' competitive positioning against larger med-tech players by offering differentiated, integrated solutions.
  • Despite short-term cash flow pressures, Avanos maintains a solid balance sheet with $65.6 million in cash and manageable debt of $98.2 million as of Q1 FY26, and its transformation efforts—including divestitures of non-core assets like the HA product line—are streamlining the business toward higher-margin, faster-growing segments, setting the stage for improved operational efficiency and margin expansion as cost management initiatives begin to take effect.
▼ Bear case
  • Avanos Medical's Pain Management & Recovery segment showed minimal growth in Q1 FY26 with only 0.2% year-over-year revenue increase, underscoring persistent weakness in its surgical pain and recovery business, which declined 11.0% and raises concerns about the sustainability of its non-opioid pain portfolio amid intense competition from larger players like Stryker, Medtronic, and Boston Scientific that have broader portfolios and greater scale.
  • The company experienced a significant cash flow deterioration in Q1 FY26, with cash used in operations of $12.3 million compared to $25.7 million provided a year ago, and free cash flow turned negative at $16.6 million versus $19.0 million inflow in the prior year, signaling worsening working capital trends and operational strain that could hinder investment in growth initiatives despite the pending acquisition.
  • Avanos continues to carry a high debt load of $98.2 million as of March 31, 2026, and while not excessive relative to its size, the reliance on term loan financing introduces refinancing risk and limits financial flexibility, particularly if interest rates remain elevated or if the AIP acquisition faces delays or regulatory hurdles that prolong uncertainty.
  • The Corporate and Other segment reported an 81.4% year-over-year revenue decline in Q1 FY26, reflecting ongoing struggles with non-core or underperforming businesses, and although divestitures are underway, the persistent drag suggests that transformation efforts may be taking longer than anticipated, potentially delaying the full realization of cost savings and strategic focus benefits.
  • Despite positive NOPAIN Act developments, the Pain Management & Recovery segment still reported an operating loss of $1.8 million in Q1 FY26, compared to $0.2 million income a year ago, indicating that reimbursement tailwinds have not yet translated into profitability, and the segment remains under pressure from pricing, mix, and volume challenges that could persist even with favorable policy changes.

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 ABT Abbott Laboratories 201.40 Bn27.984.4634.05 Bn
2 SYK Stryker Corp 122.29 Bn36.604.8414.72 Bn
3 MDT Medtronic plc 105.01 Bn21.732.8927.96 Bn
4 BSX Boston Scientific Corp 64.81 Bn18.163.1411.03 Bn
5 EW Edwards Lifesciences Corp 55.28 Bn2,354.768.770.60 Bn
6 DXCM Dexcom Inc 29.06 Bn29.176.03-
7 PHG Koninklijke Philips Nv 29.02 Bn22.061.429.48 Bn
8 GEHC GE HealthCare Technologies Inc. 28.27 Bn14.301.3510.14 Bn